Advertisement
Australia markets close in 2 hours 14 minutes

  • ALL ORDS

    7,850.50
    -87.00 (-1.10%)
     

  • ASX 200

    7,589.10
    -93.90 (-1.22%)
     

  • AUD/USD

    0.6525
    +0.0002 (+0.03%)
     

  • OIL

    83.80
    +0.23 (+0.28%)
     

  • GOLD

    2,344.20
    +1.70 (+0.07%)
     

  • Bitcoin AUD

    98,667.06
    +89.64 (+0.09%)
     

  • CMC Crypto 200

    1,389.80
    +7.23 (+0.52%)
     

  • AUD/EUR

    0.6082
    +0.0009 (+0.14%)
     

  • AUD/NZD

    1.0951
    -0.0007 (-0.06%)
     

  • NZX 50

    11,828.25
    -118.18 (-0.99%)
     

  • NASDAQ

    17,430.50
    -96.30 (-0.55%)
     

  • FTSE

    8,078.86
    +38.48 (+0.48%)
     

  • Dow Jones

    38,085.80
    -375.12 (-0.98%)
     

  • DAX

    17,917.28
    -171.42 (-0.95%)
     

  • Hang Seng

    17,588.62
    +304.08 (+1.76%)
     

  • NIKKEI 225

    37,953.12
    +324.64 (+0.86%)
     

Aziyo Biologics to Report First Quarter 2021 Financial Results on Tuesday, May 4, 2021

Aziyo Biologics
·1-min read

SILVER SPRING, Md., April 20, 2021 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today announced that it plans to release its first quarter earnings results after market close on Tuesday, May 4, 2021. Management will host a conference call to review the company’s financial performance starting at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on the same day. The conference call will be concurrently webcast.

The link to the webcast will be available on the Aziyo website at www.aziyo.com under the investor relations section and will be archived for future reference. To listen to the conference call, please dial (800) 708-4539 (US/Canada) or (847) 619-6396 (International) and use the conference ID number 50150586 approximately ten minutes prior to the start time.

About Aziyo Biologics
Aziyo Biologics is a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, concentrating on patients receiving implantable medical devices. Since its founding in 2015, the Company has created a portfolio of commercial-stage products used in cardiovascular, orthopedic, and reconstructive specialties. For more information, visit www.Aziyo.com.

Investors:
Leigh Salvo
Gilmartin Group
investors@aziyo.com

Media:
Courtney Guyer
Aziyo Biologics, Inc.
PR@aziyo.com